“The current circumstance has exposed some structural weaknesses from the EU’s medicines offer chain and also a superior dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides reported. She encouraged that provide chain problems be dealt with within an EU pharmaceutical tactic predicted being introduced by the end of